Molecular modeling has demonstrated that genetic fusion of DR5-B with the SRH and iRGD peptides not only enables the engagement of additional tumor targets VEGFR2 and integrin αvβ3/NRP-1, but also improves the interaction with DR5 receptor. This evidence concerns the gene NRP1 and neoplasm.